MedPath

Irritable Bowel Syndrome and Lactibiane Tolerance

Not Applicable
Completed
Conditions
Irritable Bowel Syndrome
Registration Number
NCT01529359
Lead Sponsor
PiLeJe
Brief Summary

The purpose of this study is to evaluate the effects of a probiotic combination (Lactibiane Tolerance) on the severity of symptoms in patients with irritable bowel syndrome (IBS).

Detailed Description

The primary purpose of this study is to evaluate the effects of a probiotic combination (Lactibiane Tolerance) on the severity of symptoms in patients with irritable bowel syndrome (IBS).

The secondary purposes are to evaluate the effects of the intervention on:

* quality of life

* severity of fatigue, anxiety and depression

* levels of inflammatory markers in blood and tools

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
123
Inclusion Criteria
  • Irritable bowel syndrome according to the Rome II criteria
  • 150< Francis Score < 300
  • HAD score inferior or egal to 25
Exclusion Criteria
  • History of hypersensitivity to one of the composant of the product
  • Use of probiotics or antibiotics last four weeks
  • use of prohibited drugs
  • bowel preparation for morphological examination last month
  • pregnancy or lactation
  • immundepressed or co-existing other serious illness or evolutive

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Severity of bowel symptoms according to the Francis ScoreAfter 6 weeks of complementation

The severity of bowel symptoms is evaluated with a quality of life questionnaire, the Francis Score before and after 6 weeks of complementation in placebo and verum groups.

Secondary Outcome Measures
NameTimeMethod
Impact of the intervention on immunological parameters in bloodafter 2 weeks of wash-out

The impact of the intervention on immunological parameters in blood will be measured with levels of endotoxines, ultrasensitive protein C Reactive and cytokines

Severity of Anxiety/Depressionafter 6 weeks of complementation

The level of anxiety/depression will be measured with the HAD scale

Impact of the complementation on fatigueAfter 2 weeks of wash out

The level of fatigue will be measured with the score to the fatigue Impact Scale (FIS)

Quality of lifeafter 2 weeks of wash-out

Effect of the intervention on transit and abdominal pain

Severity of bowel symptoms according to the Francis Scoreafter 2 weeks of wash-out

The severity of bowel symptoms is evaluated with the Francis Score before 6 weeks of complementation and after 2 weeks of wash-out in placebo and verum groups

severity of the anxiety/depressionafter 2 weeks of wash-out

The level of anxiety/depression will be measured with the HAD scale

Impact of the intervention on immunological parameters in stoolsafter 2 weeks of wash out

The effects of the intervention on immunological parameters in stools will be avaluated via the levels of beta-defensine 2 and sérine protease activities

Trial Locations

Locations (1)

Chu L'Archet 2

🇫🇷

Nice, Alpes Maritimes, France

Chu L'Archet 2
🇫🇷Nice, Alpes Maritimes, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.